Publication: Dengue virus infection of erythroid precursor cells is modulated by both thalassemia trait status and virus adaptation
Issued Date
2014-12-01
Resource Type
ISSN
10960341
00426822
00426822
Other identifier(s)
2-s2.0-84908432630
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Virology. Vol.471-473, (2014), 61-71
Suggested Citation
Wannapa Sornjai, Kornpat Khungwanmaythawee, Saovaros Svasti, Suthat Fucharoen, Phitchayapak Wintachai, Sutee Yoksan, Sukathida Ubol, Nitwara Wikan, Duncan R. Smith Dengue virus infection of erythroid precursor cells is modulated by both thalassemia trait status and virus adaptation. Virology. Vol.471-473, (2014), 61-71. doi:10.1016/j.virol.2014.10.004 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33943
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Dengue virus infection of erythroid precursor cells is modulated by both thalassemia trait status and virus adaptation
Other Contributor(s)
Abstract
© 2014 Elsevier Inc. Dengue is the most significant arthropod borne viral disease worldwide, and infection with the dengue virus causes a wide range of symptoms in humans, including bone marrow suppression. While the target cells of the virus remain poorly characterized, cells of the myeloid lineage have been shown to be important mediators of the disease. This study sought to determine whether erythroid precursor cells were susceptible to dengue virus infection, and whether erythroid cells from thalassemia trait carriers showed any protection against infection. Infection with a laboratory adapted high passage DENV-2 resulted in high levels of infection during certain stages of differentiation, and cells derived from thalassemia trait carriers showed significantly reduced susceptibility to dengue virus infection. Infection with low passage isolates resulted in only scattered cells showing evidence of infection, but high bystander apoptosis that was reduced by both a caspase 8 inhibitor and anti-tumor necrosis factor 1 receptor antibodies.